Compare Novo Nordisk A/S (NVO) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $44.91 (market cap $200.69B), while Direxion Daily Semiconductor Bull 3X Shares trades at $122.95. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals.
| NVO | SOXL | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $300.77 |
52-Week Low | $35.29 | $28.60 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, gained 5.19% to $123.37, reflecting strong bullish momentum in semiconductor stocks. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights ongoing institutional interest in semiconductor ETFs despite warnings about potential short-term volatility and tariff concerns from US trade policy discussions.
The outlook for SOXL remains tied to semiconductor sector performance, with AI demand providing long-term support. However, investors face significant risks from volatility decay inherent in leveraged ETFs, potential tariff impacts, and crowded trading positioning that could trigger sharp corrections. The ETF's performance is highly correlated with major semiconductor stocks like NVIDIA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
